FDAnews
www.fdanews.com/articles/85043-jerini-gives-development-update-on-icatibant

JERINI GIVES DEVELOPMENT UPDATE ON ICATIBANT

March 6, 2006

Jerini has reported clinical trial progress from its ongoing Phase III clinical trial for hereditary angioedema (HAE). One hundred and fifty-three subcutaneous open-label treatments with Icatibant have been administered for abdominal, cutaneous, and laryngeal HAE attacks, with 91 percent of patients being treated with only a single injection within 24 hours. Eight percent of patients received a second injection and one percent received three injections within 24 hours.

In the ongoing Phase III trials, patients completing the randomized study phase are eligible to receive Icatibant in the open-label study phase. In addition, 48 percent of participating Phase III patients have been treated with Icatibant in multiple HAE attacks, with one patient receiving more than 30 treatments.